


Pseudoresponse

- Antiangiogenic agents
- Have been tested in recent high-grade glioma treatment trials
 - **Avastin (Bevacizumab)**, an anti-VEGF antibody, and
 - **Cediranib**, a VEGF receptor tyrosine kinase inhibitor.
- Produce a rapid decrease in contrast enhancement with a high response rate and 6-month progression-free survival, but with rather modest effects on overall survival

Pseudoresponse



Caution

- Early decrease in contrast enhancement suggests a change in vascular permeability, with a “normalization” of the BBB,
- Rather than a true tumor reduction, as being the underlying cause of the improvement.
- radiologic response should be interpreted with caution
- A very brief response—perhaps lasting just a few days or weeks and therefore termed “pseudoresponse”